Efficacy of the drug Vitalux Plus of patients with dry form of age-related macular degeneration
https://doi.org/10.18008/1816-5095-2013-2-61-64
Abstract
Purpose: To analyze the data, visometry and the thickness of the fovea, patients with dry form of age-related macular degeneration (AMD) after dosing Vitalux Plus.
Methods: We observed 25 patients with dry form of AMD. Visometry and optical coherence tomography of the macula was assessed at 1 and 3 months after treatment Vitalux Plus.
Results: In the study group according to visometry and optical coherence tomography was found a positive trend. In the course of our research in 65.3 % of the thickness of the fovea increased, probably by increasing the layer of pigment epithelium. Improvement in the layer of pigment epithelium was observed mainly in patients with early-stage AMD, and in this group also found improvement in visual acuity and more motivated to treatment and further outpatient observation.
Conclusion: During the observation period, all patients with dry form of AMD, the stabilization of visual acuity. In the main group on the background of the drug Vitalux Plus objective indicators showed improvement according to retinal optical coherence tomography.
In the analysis of the results showed a positive therapeutic effect in patients Vitalux Plus, especially with early dry form of AMD.
About the Authors
I. R. Gazizova
ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
Z. F. Kamaltdinova
ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
F. F. Fajzulina
МБУЗ ГКБ № 10
Russian Federation
Russian Federation
References
1. Будзинская М. В., Воробьева М. В., Киселева Т. Н., Лагутина Ю. М., Полунин Г. С. Современные подходы к лечению и профилактике возрастной макулярной дегенерации // Клиническая офтальмология. 2007. Т. 8, № 2. С. 78‑82.
2. Ермакова Н. А., Рабданова О. Ц. Основные этиологические факторы и патогенетические механизмы развития возрастной макулярной дегенерации // Клиническая офтальмология. 2007. Т. 8, № 3. С. 125‑128.
3. Журавлева Л. В. Оценка качества жизни больных поздней стадии ВМД (по результатам опросника NEI VFQ — 25) // Материалы IX съезда офтальмологов России. М.,2010. С. 263.
4. Мухина М. А., Сотникова Е. В., Кутенова О. М. Социальная значимость и актуальность проблемы лечения макулодистрофии // Материалы VII съезда офтальмологов России. М., 2000. С. 220.
5. Урнева Е. М., Алпатов С. А., Аверьянов Д. А., Щуко А. Г., Малышев В. В. Оценка развития возрастной макулярной дегенерации с помощью оптической когерентной томографии высокого разрешения // Сибирский медицинский журнал. 2009. № 4. С. 29‑33.
6. Age — Related Eye Disease Study Research Group. A randomized, placebo — controlled, clinical trial of high — dose supplementation with vitamins C and E and beta carotene for age — related cataract and vision loss: AREDS report no. 9 // Arch Ophthalmol. 2001. V. 119. Р. 1439‑1452.
7. Johnson E. J., Chung H. Y., Caldarella S. M., et al. The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation //Am. J. Clin. Nutr. 2008. V. 87. Р. 1521‑1529.
8. Sahel J. A., Bandello F., et al. Healths — related quality of life and utility in patient with age — related macular degeneration // Arch. Ophthalmol. 2007. V. 125. P. 945‑951.
9. Trieschmann M., Beatty S., Nolan J. M., et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study // Exp. Eye Res. 2007. V. 84. Р.718‑728.
Review
For citations:
Gazizova I.R., Kamaltdinova Z.F., Fajzulina F.F. Efficacy of the drug Vitalux Plus of patients with dry form of age-related macular degeneration. Ophthalmology in Russia. 2013;10(2):61-64. (In Russ.) https://doi.org/10.18008/1816-5095-2013-2-61-64
Views:
1454
Email this article 